Mesoblast Ltd (MSB) - Net Assets

Latest as of June 2025: AU$597.44 Million AUD ≈ $422.73 Million USD

Based on the latest financial reports, Mesoblast Ltd (MSB) has net assets worth AU$597.44 Million AUD (≈ $422.73 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$784.68 Million ≈ $555.21 Million USD) and total liabilities (AU$187.24 Million ≈ $132.48 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Mesoblast Ltd to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$597.44 Million
% of Total Assets 76.14%
Annual Growth Rate 18.74%
5-Year Change 2.76%
10-Year Change 13.12%
Growth Volatility 274.19

Mesoblast Ltd - Net Assets Trend (2005–2025)

This chart illustrates how Mesoblast Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Mesoblast Ltd's balance sheet for the complete picture of this company's asset base.

Annual Net Assets for Mesoblast Ltd (2005–2025)

The table below shows the annual net assets of Mesoblast Ltd from 2005 to 2025. For live valuation and market cap data, see market value of Mesoblast Ltd.

Year Net Assets Change
2025-06-30 AU$597.44 Million
≈ $422.73 Million		 +24.38%
2024-06-30 AU$480.36 Million
≈ $339.88 Million		 -4.28%
2023-06-30 AU$501.84 Million
≈ $355.08 Million		 +0.96%
2022-06-30 AU$497.04 Million
≈ $351.69 Million		 -14.51%
2021-06-30 AU$581.40 Million
≈ $411.38 Million		 +5.84%
2020-06-30 AU$549.33 Million
≈ $388.68 Million		 +14.19%
2019-06-30 AU$481.05 Million
≈ $340.37 Million		 -11.90%
2018-06-30 AU$546.01 Million
≈ $386.34 Million		 +5.66%
2017-06-30 AU$516.77 Million
≈ $365.64 Million		 -2.16%
2016-06-30 AU$528.16 Million
≈ $373.71 Million		 -13.33%
2015-06-30 AU$609.36 Million
≈ $431.16 Million		 +6.58%
2014-06-30 AU$571.72 Million
≈ $404.53 Million		 -9.29%
2013-06-30 AU$630.27 Million
≈ $445.95 Million		 +31.62%
2012-06-30 AU$478.85 Million
≈ $338.82 Million		 -7.17%
2011-06-30 AU$515.84 Million
≈ $364.99 Million		 +1260.38%
2010-06-30 AU$37.92 Million
≈ $26.83 Million		 +47.03%
2009-06-30 AU$25.79 Million
≈ $18.25 Million		 -1.63%
2008-06-30 AU$26.22 Million
≈ $18.55 Million		 +27.64%
2007-06-30 AU$20.54 Million
≈ $14.53 Million		 +71.66%
2006-06-30 AU$11.97 Million
≈ $8.47 Million		 -37.89%
2005-06-30 AU$19.26 Million
≈ $13.63 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Mesoblast Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 100943263100.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Common Stock AU$1.51 Billion 252.55%
Other Comprehensive Income AU$99.50 Million 16.65%
Total Equity AU$597.44 Million 100.00%

Mesoblast Ltd Competitors by Market Cap

The table below lists competitors of Mesoblast Ltd ranked by their market capitalization.

Company Market Cap
Engie Energia Chile SA
SN:ECL
 $2.00 Billion
Shanghai Bright Power Semiconductor
SHG:688368
 $2.00 Billion
Establishment Labs Holdings Inc
NASDAQ:ESTA
 $2.00 Billion
Sinosoft Co Ltd
SHG:603927
 $2.00 Billion
Xiamen Solex High-Tech Industries Co Ltd
SHG:603992
 $2.00 Billion
Entra ASA
OL:ENTRA
 $2.00 Billion
Scatec Solar OL
OL:SCATC
 $1.99 Billion
Hangzhou Steam Turbine
SHE:200771
 $1.99 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Mesoblast Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 480,355,000 to 597,442,000, a change of 117,087,000 (24.4%).
  • Net loss of 102,142,000 reduced equity.
  • Share repurchases of 168,029,000 reduced equity.
  • New share issuances of 161,205,000 increased equity.
  • Other comprehensive income increased equity by 21,196,000.
  • Other factors increased equity by 204,857,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income AU$-102.14 Million -17.1%
Share Repurchases AU$168.03 Million -28.12%
Share Issuances AU$161.21 Million +26.98%
Other Comprehensive Income AU$21.20 Million +3.55%
Other Changes AU$204.86 Million +34.29%
Total Change AU$- 24.38%

Book Value vs Market Value Analysis

This analysis compares Mesoblast Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 4.21x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 61.41x to 4.21x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2005-06-30 AU$0.04 AU$2.20 x
2006-06-30 AU$0.02 AU$2.20 x
2007-06-30 AU$0.04 AU$2.20 x
2008-06-30 AU$0.05 AU$2.20 x
2009-06-30 AU$0.05 AU$2.20 x
2010-06-30 AU$0.07 AU$2.20 x
2011-06-30 AU$0.96 AU$2.20 x
2012-06-30 AU$0.89 AU$2.20 x
2013-06-30 AU$1.17 AU$2.20 x
2014-06-30 AU$1.06 AU$2.20 x
2015-06-30 AU$1.13 AU$2.20 x
2016-06-30 AU$0.98 AU$2.20 x
2017-06-30 AU$0.96 AU$2.20 x
2018-06-30 AU$1.17 AU$2.20 x
2019-06-30 AU$0.89 AU$2.20 x
2020-06-30 AU$1.02 AU$2.20 x
2021-06-30 AU$0.96 AU$2.20 x
2022-06-30 AU$0.77 AU$2.20 x
2023-06-30 AU$0.68 AU$2.20 x
2024-06-30 AU$0.49 AU$2.20 x
2025-06-30 AU$0.52 AU$2.20 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Mesoblast Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -17.10%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -593.92%
  • • Asset Turnover: 0.02x
  • • Equity Multiplier: 1.31x
  • Recent ROE (-17.10%) is above the historical average (-20.35%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2005 -7.63% -292.39% 0.02x 1.11x AU$-3.40 Million
2006 -69.36% -294.09% 0.17x 1.37x AU$-9.50 Million
2007 -42.49% -519.74% 0.08x 1.03x AU$-10.78 Million
2008 -38.38% -1105.99% 0.03x 1.06x AU$-12.68 Million
2009 -47.64% -1379.29% 0.03x 1.05x AU$-14.86 Million
2010 -38.98% -268743.55% 0.00x 1.04x AU$-18.57 Million
2011 17.56% 74.93% 0.16x 1.48x AU$39.02 Million
2012 -14.86% -185.86% 0.05x 1.50x AU$-119.03 Million
2013 -9.78% -214.21% 0.03x 1.40x AU$-124.69 Million
2014 -14.16% -311.62% 0.03x 1.57x AU$-138.13 Million
2015 -19.59% -502.64% 0.02x 1.67x AU$-180.30 Million
2016 -0.78% -9.70% 0.06x 1.30x AU$-56.94 Million
2017 -14.86% -3184.70% 0.00x 1.27x AU$-128.49 Million
2018 -6.46% -203.51% 0.03x 1.27x AU$-89.89 Million
2019 -18.67% -537.01% 0.03x 1.36x AU$-137.90 Million
2020 -14.19% -242.38% 0.04x 1.34x AU$-132.87 Million
2021 -17.00% -1325.25% 0.01x 1.28x AU$-156.95 Million
2022 -18.38% -894.59% 0.02x 1.33x AU$-141.05 Million
2023 -16.32% -1091.71% 0.01x 1.33x AU$-132.07 Million
2024 -18.31% -1490.27% 0.01x 1.39x AU$-135.99 Million
2025 -17.10% -593.92% 0.02x 1.31x AU$-161.89 Million

Industry Comparison

This section compares Mesoblast Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $8,264,074
  • Average return on equity (ROE) among peers: -154.79%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Mesoblast Ltd (MSB) AU$597.44 Million -7.63% 0.31x $2.00 Billion
Adalta Ltd (1AD) $172.82K -722.64% 1.66x $6.50 Million
Algorae Pharmaceuticals Ltd (1AI) $-1.33 Million 0.00% 0.00x $20.04 Million
ACRUX Ltd (ACR) $11.66 Million -0.09% 0.10x $3.20 Million
Actinogen Medical Ltd (ACW) $13.41 Million -80.20% 0.13x $103.45 Million
Argenica Therapeutics Ltd (AGN) $7.24 Million -99.08% 0.53x $15.45 Million
Arovella Therapeutics Ltd (ALA) $11.23 Million -77.89% 0.18x $59.79 Million
Anatara Lifesciences Ltd (ANR) $-16.00K 0.00% 0.00x $1.57 Million
Alterity Therapeutics Ltd (ATH) $13.80 Million -138.60% 0.39x $76.95 Million
Amplia Therapeutics Ltd (ATX) $21.02 Million -31.26% 0.09x $54.45 Million
Avecho Biotechnology Ltd (AVE) $5.45 Million -398.12% 0.01x $31.19 Million

About Mesoblast Ltd

AU:MSB Australia Biotechnology
Market Cap
$2.00 Billion
AU$2.82 Billion AUD
Market Cap Rank
#6270 Global
#144 in Australia
Share Price
AU$2.20
Change (1 day)
+0.00%
52-Week Range
AU$1.57 - AU$3.07
All Time High
AU$5.21
Categories
Companies in Australia Biotechnology
About

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic… Read more